(NewsNation) —A recent study has cast doubt about the efficacy of certain cancer drugs, leaving many patients and health care professionals grappling with concerns about the treatments’ potential benefits.

According to the findings from a team from the University of Gothenburg in Sweeden, a portion of cancer drugs currently on the market may offer little to no significant clinical benefit to patients.

The team looked at the scientific evidence surrounding nearly two dozen new cancer drugs.

Results of the study showed that only seven of the 22 drugs tested demonstrated a clear benefit for cancer patients. 

The study assessed a drug’s ability to extend survival rates, improve quality of life or deliver other meaningful outcomes for patients.

While acknowledging that advancements have been made in cancer treatment, the researchers caution against assuming that all cancer drugs uniformly offer substantial benefits.

Oncologists and health care providers who have been recommending certain cancer drugs now find themselves reevaluating their treatment strategies.

Pharmaceutical industry representatives emphasized that the development and approval of cancer drugs are based on rigorous clinical trials and regulatory processes, aimed at ensuring patient safety and treatment efficacy.

Drug representatives assert that individual patient responses to treatments can vary, and some patients do benefit significantly from the drugs in question.

The study’s impact on treatment guidelines and drug recommendations is yet to be fully understood, as the medical community continues to grapples with the complex reality of cancer treatment.